ArticleInternational journal of telemedicine and applications2025
Design and Development of an Electronic Platform for Allergen Immunotherapy in China.
Article in International journal of telemedicine and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design and Development of an Electronic Platform for Allergen Immunotherapy in China.International journal of telemedicine and applications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A variety of patient populations receive allergen immunotherapy (AIT), but clinicians still lack an effective electronic platform to manage them. Methods: We designed a platform based on the framework of value set extraction standardization, integration, and structurization. Average medication scoring (AMS) and other electronic medical records were developed and stored on a MySQL database. Data storage is hosted on cloud servers, linked to a mobile application, Bluetooth lung function monitoring, and a dedicated website that acts as a front-end. Results: Since 2015, 23,847 patients in 48 hospitals with AIT prescriptions were included. Of these patients, the median age was 15 (interquartile range, 10-27) years. Allergic rhinitis was the most common disorder and accounted for 9753 (40.9%) of the cases. Five hundred and thirty-three basic data elements and six independent modules were constructed for the platform to facilitate the physicians in establishing SCIT projects, symptom scores, AMS, lung function tests, and follow-up appointments. One hundred and twelve drugs including 10 dosage forms were identified from an internal list of the dataset. The unit score was calculated based on the action mechanism of the medicine. The AMS formula has six parameters: total dose, frequency, period, unit score, unit dose, and follow-up days. A lower AMS suggests a better treatment efficacy. Conclusion: The program presented our experience in developing, pilot testing, and evaluating an electronic AIT platform, and future research would indicate whether the template could be made more time efficient in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.